SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Faeth Reports Positive Preliminary Phase 2 Trial Results

Faeth said preliminary Phase 2 results for PIKTOR in an endometrial cancer trial were positive.

FTH
SquawkNews Desk 1 updates Updated Nov 09, 2026, 12:23 PM UTC

Story updates

12:23:19 PM UTC
SquawkNews
Faeth Therapeutics reported positive preliminary Phase 2 results for PIKTOR plus paclitaxel in advanced endometrial cancer, with a 33% confirmed response rate.Key Highlights:Original SEC Filing: Faeth Therapeutics, Inc. [ FTH ] - 8-K - Nov. 09, 2026This is an AI-powered summary. It may contain inac…

Related stories

Spruce Biosciences Q3 Net Loss Widens on Higher R&D Costs M impact | EQUITY | Nov 09, 2026, 01:13 PM UTC SharpLink Gaming Q3 Revenue Beats Estimates SharpLink Gaming reported Q3 revenue above estimates, citing favorable ETH market conditions. M impact | EQUITY | Nov 09, 2026, 01:09 PM UTC Alla Reports Quarterly Net Profit of 21.9 Million Baht M impact | EQUITY | Nov 09, 2026, 01:08 PM UTC Global Ship Lease Reports Third-Quarter 2026 Results Global Ship Lease reported third-quarter 2026 results, increased its annualized dividend to $2.75 per Class A common share and secured a $1.0 billion credit facility. Contract cove M impact | EQUITY | Nov 09, 2026, 01:07 PM UTC Intuitive Machines Selected for NASA’s CLPS 2 Contract The multiple-award IDIQ has a $10B combined ceiling across awardees, potentially rising to $15B if NASA exercises a five-year option. The contract runs approximately 10 years, with M impact | EQUITY | Nov 09, 2026, 01:07 PM UTC IGC Pharma Reports Third-Quarter 2026 Results and Business Update The company says CALMA randomized 170 participants; topline results are expected after last patient-last dose, database lock and unblinding. M impact | EQUITY | Nov 09, 2026, 01:06 PM UTC